-
1
-
-
0035413599
-
Phosphoinositideregulated kinases and phosphoinositide phosphatases
-
PMID:11749378
-
Leslie NR, Biondi RM, Alessi DR. Phosphoinositideregulated kinases and phosphoinositide phosphatases. Chem Rev 2001; 101:2365-80; PMID:11749378; http://dx.doi.org/10.1021/cr000091i
-
(2001)
Chem Rev
, vol.101
, pp. 2365-2380
-
-
Leslie, N.R.1
Biondi, R.M.2
Alessi, D.R.3
-
2
-
-
84884903877
-
Activator or inhibitor? GSK-3 as a new drug target
-
PMID:23643839
-
Takahashi-Yanaga F. Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol 2013; 86:191-9; PMID:23643839; http://dx.doi.org/10.1016/j. bcp.2013.04.022
-
(2013)
Biochem Pharmacol
, vol.86
, pp. 191-199
-
-
Takahashi-Yanaga, F.1
-
3
-
-
84884688237
-
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells
-
PMID:23877009
-
Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Mol Pharmacol 2013; 84:562-71; PMID:23877009; http://dx.doi.org/10.1124/mol.113. 088005
-
(2013)
Mol Pharmacol
, vol.84
, pp. 562-571
-
-
Sajithlal, G.B.1
Hamed, H.A.2
Cruickshanks, N.3
Booth, L.4
Tavallai, S.5
Syed, J.6
Grant, S.7
Poklepovic, A.8
Dent, P.9
-
4
-
-
84874334011
-
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibitioninduced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism
-
PMID:23243017
-
Rahmani M, Aust MM, Attkisson E, Williams DC Jr., Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibitioninduced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res 2013; 73:1340-51; PMID:23243017; http://dx.doi.org/10.1158/0008-5472.CAN-12-1365
-
(2013)
Cancer Res
, vol.73
, pp. 1340-1351
-
-
Rahmani, M.1
Aust, M.M.2
Attkisson, E.3
Williams Jr., D.C.4
Ferreira-Gonzalez, A.5
Grant, S.6
-
5
-
-
77953523121
-
Recent advances in neuroblastoma
-
PMID:20558371
-
Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362:2202-11; PMID:20558371; http://dx.doi.org/10.1056/NEJMra0804577
-
(2010)
N Engl J Med
, vol.362
, pp. 2202-2211
-
-
Maris, J.M.1
-
6
-
-
0030919377
-
Neuroblastoma in adults and adolescents: An indolent course with poor survival
-
DOI 10.1002/(SICI)1097-0142(19970515)79:10<2028::AID-CNCR26>3.0. CO;2-V
-
Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997; 79:2028-35; PMID:9149032; http://dx.doi.org/10.1002/(SICI)1097-0142(19970515)79: 10<2028::AIDCNCR26>3.0.CO;2-V (Pubitemid 27200389)
-
(1997)
Cancer
, vol.79
, Issue.10
, pp. 2028-2035
-
-
Franks, L.M.1
Bollen, A.2
Seeger, R.C.3
Stram, D.O.4
Matthay, K.K.5
-
7
-
-
84899842513
-
Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth
-
PMID:24521712
-
Carter YM, Kunnimalaiyaan S, Chen H, Gamblin TC, Kunnimalaiyaan M. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther 2014; 15:510-5; PMID:24521712; http://dx.doi.org/10.4161/cbt.28015
-
(2014)
Cancer Biol Ther
, vol.15
, pp. 510-515
-
-
Carter, Y.M.1
Kunnimalaiyaan, S.2
Chen, H.3
Gamblin, T.C.4
Kunnimalaiyaan, M.5
-
8
-
-
84886259126
-
Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma
-
PMID:24034838
-
Madhunapantula SV, Sharma A, Gowda R, Robertson GP. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2013; 26:886-99; PMID:24034838; http://dx.doi.org/10.1111/ pcmr.12156
-
(2013)
Pigment Cell Melanoma Res
, vol.26
, pp. 886-899
-
-
Madhunapantula, S.V.1
Sharma, A.2
Gowda, R.3
Robertson, G.P.4
-
9
-
-
71649106231
-
Glycogen synthase kinase-3: A new therapeutic target in renal cell carcinoma
-
PMID:19920820
-
Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A, Oya M, Billadeau D, Motoyama T, Tomita Y. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer 2009; 101:2005-14; PMID:19920820; http://dx.doi.org/10.1038/sj.bjc.6605437
-
(2009)
Br J Cancer
, vol.101
, pp. 2005-2014
-
-
Bilim, V.1
Ougolkov, A.2
Yuuki, K.3
Naito, S.4
Kawazoe, H.5
Muto, A.6
Oya, M.7
Billadeau, D.8
Motoyama, T.9
Tomita, Y.10
-
10
-
-
84864610364
-
The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice
-
PMID:22698482
-
Ahn SW, Kim JE, Park KS, Choi WJ, Hong YH, Kim SM, Kim SH, Lee KW, Sung JJ. The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice. J Neurol Sci 2012; 320:1-5; PMID:22698482; http://dx.doi.org/10.1016/j.jns.2012.05.038
-
(2012)
J Neurol Sci
, vol.320
, pp. 1-5
-
-
Ahn, S.W.1
Kim, J.E.2
Park, K.S.3
Choi, W.J.4
Hong, Y.H.5
Kim, S.M.6
Kim, S.H.7
Lee, K.W.8
Sung, J.J.9
-
11
-
-
84896691989
-
Sequential dosing in chemosensitization: Targeting the PI3K/Akt/mTOR pathway in neuroblastoma
-
PMID:24391739
-
Westhoff MA, Faham N, Marx D, Nonnenmacher L, Jennewein C, Enzenmüller S, Gonzalez P, Fulda S, Debatin KM. Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma. PLoS One 2013; 8:e83128; PMID:24391739; http://dx.doi.org/10.1371/journal.pone. 0083128
-
(2013)
PLoS One
, vol.8
-
-
Westhoff, M.A.1
Faham, N.2
Marx, D.3
Nonnenmacher, L.4
Jennewein, C.5
Enzenmüller, S.6
Gonzalez, P.7
Fulda, S.8
Debatin, K.M.9
|